{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', \"they will be under the same strict confidentiality requirements. The study participant's contact\", 'information will be securely stored at each clinical site for internal use during the study. At the end of the', 'study, all records will continue to be kept in a secure location for as long a period as dictated by the', 'reviewing IRB, Institutional policies, or sponsor requirements.', 'Study participant research data, which is for purposes of statistical analysis and scientific reporting, will', 'be transmitted to and stored at the University of Pittsburgh Data Coordinating Center. This will not include', \"the participant's contact or identifying information. Rather, individual participants and their research data\", 'will be identified by a unique study identification number. The study data entry and study management', 'systems used by clinical sites and by the Data Coordinating Center research staff will be secured and', 'password protected. At the end of the study, all study databases will be de-identified and archived at the', 'CRHC DC Data Coordinating Center.', '10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA', 'Data collected for this study will be analyzed and stored at the University of Pittsburgh Center for Health', 'Care Data Center (CRHC DC) Data Coordinating Center (DCC). After the study is completed, the de-', 'identified, archived data will be transmitted to and stored at the University of Pittsburgh CRHC DC', 'Repository, for use by other researchers including those outside of the study. Permission to transmit data', 'to the University of Pittsburgh CRHC DC Repository will be included in the informed consent.', \"With the participant's approval and as approved by local Institutional Review Boards (IRBs), de-identified\", 'biological samples will be stored at the University of North Caroline Francis Owen Blood Research', 'Laboratory, Chapel Hill, NC with the same goal as the sharing of data with the University of Pittsburgh', 'CRHC DC Repository. These samples could be used to research the causes of von Willebrand disease and', 'its complications and other conditions for which individuals with congenital bleeding disorders are at', 'increased risk, and to improve treatment. The CRHC DC Data Repository will also be provided with a code-', 'link that will allow linking the biological specimens with the phenotypic data from each participant,', 'maintaining the blinding of the identity of the participant.', 'During the conduct of the study, an individual participant can choose to withdraw consent to have', 'biological specimens stored for future research. However, withdrawal of consent with regard to bio-', 'sample storage may not be possible after the study is completed. When the study is completed, access', 'to study data will be provided through the University of Pittsburgh CRHC DC Repository and samples will', 'be provided through University of North Carolina Francis Owen Blood Research Laboratory, Chapel Hill.', 'Study Organization and Administration. The Clinical Coordinating Center (CCC) for this multi-site clinical', 'trial will be headquartered at the University of Pittsburgh under the direction of Dr. Ragni, PI. The Data', 'Coordinating Center (DCC) for this multi-site clinical trial will the Clinical Trials and Data Coordinating', 'Center (CCDC), part of the Center for Research on Health Care Data Center (CRHC DC), University of', 'Pittsburgh under the direction of Dr. Doris Rubio, Co-Investigator. Dr. Ragni, an expert in VWD, will direct', 'and be responsible for the scientific and clinical performance of the trial, and regulatory aspects of the', 'trial, including NHLBI and IRB submissions. She will work closely with Dr. Rubio, an expert in statistics and', '39']['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'trial design, who will oversee data management and statistical plan and analyses. The CCC and DCC will', 'analyze the data, prepare publications, and jointly monitor the conduct of the study, including', 'recruitment, data quality, and protocol compliance and adherence. The CCC PI and DCC PI will work', 'collaboratively to assure the trial is completed on-time and on-budget. They will meet weekly or biweekly', 'to manage and monitor the trial, review enrollment, assess milestones, identify barriers, and implement', 'strategies and approaches to resolve them in a timely fashion.', 'Key Roles and Study Governance', 'Principal Investigator', 'Medical Monitor', 'Margaret V. Ragni, MD, MPH', 'Amy Shapiro, MD', 'Professor of Medicine and Clinical Translational', 'Director, Indiana Hemophilia & Thrombosis', 'Science, Department of Medicine', 'Center', 'Pediatric Hematology', 'University of Pittsburgh', 'Indiana University', 'School of Medicine', 'Health University Hospital', 'Hemophilia Center of Western PA (HCWP) 3636', 'Indiana Hemophilia & Thrombosis Center, Inc.', 'Boulevard of the Allies', '8326 Naab Road', 'Pittsburgh PA 15213-4306', 'Indianapolis IN 46260', '412-209-7288', '317-871-0000', 'ragni@pitt.edu', 'ashapiro@ihtc.org', 'The CCC PI and DCC PI will serve on and be advised by the Executive Committee (EC), which will also', 'include the NHLBI program officer, Nahed El Kassar, MD, PhD, who will meet monthly to set policy and', 'monitor trial operations, review project-wide issues and formulate policy regarding the conduct of the', 'trial.', 'The CCC PI and DCC PI will also serve on and be advised by the Steering Committee (SC) which will also', 'consist of 10 site HTC MDs rotating staggering 3-year terms, and a Gynecologist Consultant. The SC will', 'set policy, make decisions, and meet quarterly to review and discuss site (HTC) problems and protocol', 'barriers, and monitor and advise on trial progress, as well as safety and efficacy outcomes.', 'The Investigator Consortium Network of 19 HTC MDs and nurse coordinators will participate in monthly', 'conference calls and advise the CCC PI and DCC PI on screening, enrollment, HTC problems and barriers,', 'and clinical and safety problems that arise.', 'The trial will be monitored by an NHLBI-appointed Data and Safety Monitoring Board (DSMB), including', 'hematologists, statisticians, and clinical trial experts, who will monitor trial progress and safety, review', 'adverse events and severe adverse events and adjudicate safety and efficacy endpoints and study', 'stopping rules.', '10.1.5 SAFETY OVERSIGHT', 'Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) composed of', \"individuals with the appropriate expertise, including experts in hematology, hemostasis, women's health,\", 'and statistics. Members of the DSMB should be independent from the study conduct and free of conflict', '40']\n\n###\n\n", "completion": "END"}